IQVIA Holdings Inc. Chairman and CEO Ari Bousbib executed a sale of roughly 106,000 shares generating approximately $26.1 million in proceeds, according to an SEC Form 4 filing. The transaction represented an exercise-and-sell of stock appreciation rights scheduled to expire in February 2027, with shares sold at a weighted average price of $245.51 per share.
Following the transaction, Bousbib maintained a total beneficial position of approximately 1.4 million shares, including roughly 836,000 shares held directly and 543,000 shares held indirectly through the Orohena Trust. The sale reduced his direct holdings by approximately 11 percent while leaving his indirect interests unchanged. The weighted average sale price represented a narrow discount to the stock’s market close of $247.56 on July 29, 2026.
The timing of the share sale came on the heels of strong quarterly performance. IQVIA reported second-quarter revenue growth of 8.7 percent to $4.37 billion, alongside a 12.1 percent increase in adjusted earnings per share to $3.15. The company posted record clinical bookings of $3.15 billion with a book-to-bill ratio of 1.22 and raised full-year revenue guidance to as much as $17.475 billion.
As of the market close on July 30, 2026, IQVIA shares traded at $237.82, reflecting a market capitalization of $38.8 billion. The company reported trailing-twelve-month revenue of $17.0 billion and net income of $1.4 billion. IQVIA operates across three primary segments—Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions—serving pharmaceutical, biotechnology, and medical device clients globally. The company maintains $34.2 billion in contracted work, with approximately $9.2 billion expected to convert to revenue within one year.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI